Literature DB >> 15589559

Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity.

Vicente Molina1, Javier Sanz, Fernando Sarramea, Carlos Benito, Tomás Palomo.   

Abstract

Reduced volume and activity of the prefrontal (PF) cortical gray matter (GM) and hippocampal hypermetabolism are repeated findings in schizophrenia. There is still an information deficit about the significance of reduction of PF GM in schizophrenia, and a simultaneous study of PF anatomy and activity and limbic metabolism can contribute to fill that deficit. In order to do so, we used positron emission tomography (PET) with 18-fluoro-deoxy-glucose (FDG) during an attention task and magnetic resonance imaging (MRI) to study a sample of first episodes of psychosis. We included 21 first episodes (FE) of psychosis and 16 healthy controls. A diagnosis of schizophrenia was confirmed in the follow-up in eleven of these patients and ruled out in the remaining 10 cases. Volumes of PF GM were determined and also activity in the same region and in the hippocampus. Residual GM was estimated in the PF region as a quantitative measurement of the degree of atrophy in each individual, using age and intracranial volume data from a set of 45 healthy controls and linear regression. Patients with schizophrenia had lower PF metabolic activation and greater hippocampal activity than controls. FE patients without schizophrenia were no different in any parameter as compared to controls. Patients with schizophrenia presented an inverse and significant association between GM deficit and hippocampal activity that was not observed in controls or in patients without schizophrenia. The same association was previously described by our group using PET in the resting state in recent-onset and chronic patients with schizophrenia. These findings support a loss in PF inhibitory capacity as a possible link between anatomical and functional alterations in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15589559     DOI: 10.1016/j.jpsychires.2004.06.008

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  22 in total

1.  Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.

Authors:  Ming Teng Koh; Yi Shao; Sharon Rosenzweig-Lipson; Michela Gallagher
Journal:  Schizophr Res       Date:  2017-06-17       Impact factor: 4.939

2.  Dorsolateral prefrontal and superior temporal volume deficits in first-episode psychoses that evolve into schizophrenia.

Authors:  Vicente Molina; Javier Sanz; Fernando Sarramea; Rogelio Luque; Carlos Benito; Tomás Palomo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-09-14       Impact factor: 5.270

Review 3.  Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling.

Authors:  Carol A Tamminga; Sarah Southcott; Carolyn Sacco; Anthony D Wagner; Subroto Ghose
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

4.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

5.  Role of the prefrontal cortex in altered hippocampal-accumbens synaptic plasticity in a developmental animal model of schizophrenia.

Authors:  Pauline Belujon; Mary H Patton; Anthony A Grace
Journal:  Cereb Cortex       Date:  2012-12-12       Impact factor: 5.357

Review 6.  Neuroimaging biomarkers for early drug development in schizophrenia.

Authors:  Jason R Tregellas
Journal:  Biol Psychiatry       Date:  2013-10-04       Impact factor: 13.382

Review 7.  Hippocampal granule cell pathology in epilepsy - a possible structural basis for comorbidities of epilepsy?

Authors:  Michael S Hester; Steve C Danzer
Journal:  Epilepsy Behav       Date:  2014-01-24       Impact factor: 2.937

Review 8.  Schizophrenia: Evidence implicating hippocampal GluN2B protein and REST epigenetics in psychosis pathophysiology.

Authors:  C A Tamminga; R S Zukin
Journal:  Neuroscience       Date:  2015-07-23       Impact factor: 3.590

9.  Region-specific upregulation of parvalbumin-, but not calretinin-positive cells in the ventral hippocampus during adolescence.

Authors:  Adriana Caballero; Kimberly C Diah; Kuei Y Tseng
Journal:  Hippocampus       Date:  2013-09-02       Impact factor: 3.899

Review 10.  Treatment consideration and manifest complexity in comorbid neuropsychiatric disorders.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.